Do symptoms predict COPD in smokers?

BACKGROUND The US Preventive Services Task Force recommends against spirometry in the absence of symptoms. However, as much as 50% of COPD cases in the United States remain undiagnosed. METHODS Report of symptoms, smoking history, and spirometric data were collected from subjects screened for a work-related medical evaluation (N = 3,955). Prevalence of airflow obstruction and respiratory symptoms were assessed. Sensitivity, specificity, positive and negative predictive values, and relative risks of predicting symptoms and smoking history for COPD were calculated. RESULTS Forty-four percent of smokers in our sample had airways obstruction (AO). Of these, 36% reported a diagnosis of or treatment for COPD. Odds ratio (95% CI) for AO with smoking (> or = 20 pack-years) was 3.73 (3.12- 4.45), 1.98 (1.73-2.27) for cough, 1.79 (1.55-2.08) for dyspnea, 1.95 (1.70-2.34) for sputum, and 2.59 (2.26-2.97) for wheeze. Respiratory symptoms were reported by 92% of smokers with AO, 86% smokers with restriction, 76% smokers with normal spirometry, and 73% of nonsmokers. Sensitivity (92% vs 90%), specificity (19% vs 22%), positive (47% vs 40%) and negative (75% vs 80%) predictive values for the presence of one or more symptoms were similar between smokers and all subjects. CONCLUSIONS COPD is underdiagnosed in the United States. Symptoms are frequent in subjects with AO and increase their risk for COPD, but add little beyond age and smoking history to the predictive value of spirometry. In view of the high prevalence of symptoms and their poor predictive value, a simpler and more effective approach would be to screen older smokers.

[1]  M. Decramer,et al.  Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[2]  F. Gómez,et al.  Characteristics of patients admitted for the first time for COPD exacerbation. , 2009, Respiratory medicine.

[3]  E. Bleecker,et al.  Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers , 2009, Respiratory research.

[4]  S. Antoniu UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease , 2009, Expert opinion on pharmacotherapy.

[5]  P. Jones,et al.  Lung function decline in COPD trials , 2009, European Respiratory Journal.

[6]  D. Mannino,et al.  COPD prevalence in southeastern Kentucky: the burden of lung disease study. , 2009, Chest.

[7]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[8]  C. van Weel,et al.  Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care , 2008, European Respiratory Journal.

[9]  J Stocks,et al.  Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction , 2008, Thorax.

[10]  P. Calverley,et al.  Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.

[11]  D. Jarvis,et al.  Underestimation of airflow obstruction among young adults using FEV1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes , 2008, Thorax.

[12]  M. Barton,et al.  Screening for Chronic Obstructive Pulmonary Disease Using Spirometry: Summary of the Evidence for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.

[13]  G. Wesseling,et al.  External validation of a COPD diagnostic questionnaire , 2008, European Respiratory Journal.

[14]  H. Melbye,et al.  What role may symptoms play in the diagnosis of airflow limitation? , 2008, Scandinavian journal of primary health care.

[15]  Anastasia E. Raczek,et al.  Development and Initial Validation of a Self-Scored COPD Population Screener Questionnaire (COPD-PS) , 2008, COPD.

[16]  K. Wood,et al.  What Defines Abnormal Lung Function in Older Adults with Chronic Obstructive Pulmonary Disease? , 2008, Drugs & aging.

[17]  T. Seemungal,et al.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.

[18]  E. Bleecker,et al.  IL13 promoter polymorphism 1112C/T modulates the adverse effect of tobacco smoking on lung function. , 2007, American journal of respiratory and critical care medicine.

[19]  Shengming Liu,et al.  Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. , 2007, American journal of respiratory and critical care medicine.

[20]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[21]  D. S. Kim,et al.  Determinants of respiratory symptom development in patients with chronic airflow obstruction. , 2006, Respiratory medicine.

[22]  M. Cazzola,et al.  The role of combination therapy with corticosteroids and long-acting β2-agonists in the prevention of exacerbations in COPD , 2006, International journal of chronic obstructive pulmonary disease.

[23]  William M Vollmer,et al.  Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? , 2006, Thorax.

[24]  D. Mannino,et al.  Global burden of COPD: systematic review and meta-analysis , 2006, European Respiratory Journal.

[25]  K. Wood,et al.  FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age. , 2006, Chest.

[26]  A. Gulsvik,et al.  Post-bronchodilator spirometry reference values in adults and implications for disease management. , 2006, American journal of respiratory and critical care medicine.

[27]  K. Weiss,et al.  Spirometry use in clinical practice following diagnosis of COPD. , 2006, Chest.

[28]  D. Price,et al.  Scoring system and clinical application of COPD diagnostic questionnaires. , 2006, Chest.

[29]  D. Mannino,et al.  Lung function decline and outcomes in an elderly population , 2005, Thorax.

[30]  C. Irvin,et al.  Knowledge and use of office spirometry for the detection of chronic obstructive pulmonary disease by primary care physicians. , 2005, Respiratory care.

[31]  D. Price,et al.  Questions for COPD diagnostic screening in a primary care setting. , 2005, Respiratory medicine.

[32]  A. Lindberg,et al.  Prevalence of Chronic Obstructive Pulmonary Disease according to BTS, ERS, GOLD and ATS Criteria in Relation to Doctor’s Diagnosis, Symptoms, Age, Gender, and Smoking Habits , 2005, Respiration.

[33]  A. Gulsvik,et al.  Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study , 2005, Thorax.

[34]  R. Nordyke,et al.  Comparison of existing symptom‐based questionnaires for identifying COPD in the general practice setting , 2005, Respirology.

[35]  A. Ionescu,et al.  Attaining a correct diagnosis of COPD in general practice. , 2005, Respiratory medicine.

[36]  I. Adcock,et al.  Underuse of spirometry by general practitioners for the diagnosis of COPD in Italy. , 2005, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[37]  P. Calverley,et al.  Development of a Population-Based Screening Questionnaire for COPD , 2005, COPD.

[38]  T. Wilt,et al.  Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). , 2005, Evidence report/technology assessment.

[39]  E. Bleecker,et al.  Similarities and differences in asthma and COPD. The Dutch hypothesis. , 2004, Chest.

[40]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[41]  D. Halpin A further step in the process of developing better service and standards of care for patients with COPD , 2004 .

[42]  E. Bleecker,et al.  Changing patterns in asbestos-induced lung disease. , 2004, Chest.

[43]  J. Wedzicha,et al.  Validation of a chronic obstructive pulmonary disease screening questionnaire for population surveys. , 2004, Respiratory medicine.

[44]  S. Spencer,et al.  Bronchodilator reversibility testing in chronic obstructive pulmonary disease , 2003, Thorax.

[45]  M. Decramer,et al.  Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey , 2002, European Respiratory Journal.

[46]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[47]  D. Mannino,et al.  Chronic obstructive pulmonary disease surveillance--United States, 1971-2000. , 2002, Morbidity and mortality weekly report. Surveillance summaries.

[48]  J. Vestbo,et al.  Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? , 2002, American journal of respiratory and critical care medicine.

[49]  D. Mannino,et al.  Surveillance for asthma--United States, 1980-1999. , 2002, Morbidity and mortality weekly report. Surveillance summaries.

[50]  A. Buist,et al.  Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. , 2000, Chest.

[51]  M. Rudolf The reality of drug use in COPD: the European perspective. , 2000, Chest.

[52]  S. Yancey,et al.  Efficacy of salmeterol xinafoate in the treatment of COPD. , 1999, Chest.

[53]  J Vestbo,et al.  A 15-year follow-up study of ventilatory function in adults with asthma. , 1998, The New England journal of medicine.

[54]  Jones Js,et al.  Life in the 21st century - a vision for all. , 1998 .

[55]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[56]  C. van Weel,et al.  How to avoid underdiagnosed asthma/chronic obstructive pulmonary disease? , 1998, The Journal of asthma : official journal of the Association for the Care of Asthma.

[57]  J. Connett,et al.  Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. , 1996, American journal of respiratory and critical care medicine.

[58]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[59]  A. Buist,et al.  Chronic Obstructive Pulmonary Disease Early Intervention Trial (Lung Health Study). Baseline characteristics of randomized participants. , 1993, Chest.

[60]  R M Gardner,et al.  Reference spirometric values using techniques and equipment that meet ATS recommendations. , 2015, The American review of respiratory disease.

[61]  R. Peto,et al.  The natural history of chronic airflow obstruction. , 1977, British medical journal.